Abstract | BACKGROUND: METHODS AND RESULTS: Thirty-fourRyR2-positive CPVT patients with a history of cardiac events were enrolled. All patients had medical treatment initiated after the first symptom or diagnosis. Exercise stress tests (ESTs) were performed to evaluate the efficacy of the medical therapy. Even after the initiation of medical therapy, high-risk ventricular arrhythmias (VAs), including premature ventricular contraction couplets, bigeminy, and ventricular tachycardia, were still induced in the majority of patients (80.6%). During 7.4 years of follow-up after the diagnosis, 7 of the 34 (20.6%) patients developed fatal cardiac events. Among those 7 patients, 6 (85.7%) were not compliant with either exercise restriction or medication therapy at the time of the events. CONCLUSIONS: Even after initiation of medical treatment, high-risk VAs were induced during EST in mostRyR2-positive CPVT patients. Most fatal recurrent cardiac events occurred in patients who were noncompliant with exercise restriction and/or medical therapy. Medical management including strict exercise restriction should be emphasized to prevent recurrent cardiac event in mostRyR2-positive CPVT patients. (Circ J 2016; 80: 1907-1915).
|
Authors | Hiro Kawata, Seiko Ohno, Takeshi Aiba, Heima Sakaguchi, Aya Miyazaki, Naokata Sumitomo, Tsukasa Kamakura, Ikutaro Nakajima, Yuko Y Inoue, Koji Miyamoto, Hideo Okamura, Takashi Noda, Kengo Kusano, Shiro Kamakura, Yoshihiro Miyamoto, Isao Shiraishi, Minoru Horie, Wataru Shimizu |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 80
Issue 9
Pg. 1907-15
(Aug 25 2016)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 27452199
(Publication Type: Journal Article)
|
Chemical References |
- Ryanodine Receptor Calcium Release Channel
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Male
- Mutation
- Ryanodine Receptor Calcium Release Channel
(genetics)
- Survival Rate
- Tachycardia, Ventricular
(genetics, mortality, therapy)
|